Business
US Patent allowance for PTSD discovery programme
Solvonis Therapeutics plc has received a Notice of Allowance from the United States Patent and Trademark Office for compounds within its SVN-SDN-14 Post-Traumatic Stress Disorder discovery programme, strengthening its intellectual property as a lead compound is expected in Q1 2026. This patent covers a novel chemical series designed to modulate serotonin, dopamine, and noradrenaline pathways with improved pharmacological control, addressing historical challenges in developing effective PTSD therapeutics. The company views this as a significant milestone that enhances both the scientific and commercial foundations of its PTSD programme. Disclaimer*
About this update from Solvonis Therapeutics Plc
[{"type":"text","content":"\n\n \n\nSolvonis Therapeutics plc\n(\"Solvonis\" or the \"Company\")\n \nU.S. Patent allowance received for PTSD discovery programme\n \nDemonstrating scientific and commercial significance\n \nSolvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company developing novel medicines for high-burden central nervous system (\"CNS\") disorders, announces that it has received a Notice of Allowance (the \"Allowance\") from the United States Patent and Trademark Office (\"USPTO\") for a series of compounds within its proprietary SVN-SDN-14 Post-Traumatic Stress Disorder (\"PTSD\") discovery programme. One compound from this series is currently being evaluated alongside other candidates, with a lead compound expected to be selected in Q1 2026 in line with prior guidance.\n \nThe Allowance strengthens the intellectual property foundations of SVN-SDN-14 at an important stage as the programme advances toward lead-candidate selection. In addition to this IP milestone, the Company is highlighting the scientific significance of the newly protected compounds in addressing long-standing challenges in the development of next-generation PTSD therapeutics.\n \nScientific significance\nSVN-SDN-14 is focused on developing serotonin (\"SERT\"), dopamine (\"DAT\") and noradrenaline (\"NET\") modulators designed to support pro-social engagement and improve the effectiveness of psychological therapy in PTSD.\n \nWhile balanced modulation of these pathways is increasingly recognised as therapeutically valuable, translating this biology into a practical medicine has historically been difficult. Key challenges have included controlling duration of action, managing variability between patients, and ensuring compatibility with scalable, real-world clinical use.\n \nThe newly allowed patent covers a novel chemical series designed to retain the core SERT, DAT and NET activity underpinning the programme, while introducing greater pharmacological control through predictable metabolic deactivation. This approach is intended to maintain therapeutic effects while improving dosing flexibility, safety margins and overall suitability for clinical use.\n \nIn allowing the claims, the USPTO examiner concluded that no existing patents or publications disclosed or suggested the claimed compounds, confirming the ...